Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 1/2013

01-01-2013 | Article

Association of physical activity with all-cause mortality and incident and prevalent cardiovascular disease among patients with type 1 diabetes: the EURODIAB Prospective Complications Study

Authors: S. M. A. J. Tielemans, S. S. Soedamah-Muthu, M. De Neve, M. Toeller, N. Chaturvedi, J. H. Fuller, E. Stamatakis

Published in: Diabetologia | Issue 1/2013

Login to get access

Abstract

Aims/hypothesis

The aim of this study was to examine the association of physical activity (PA) with all-cause mortality and incident and prevalent cardiovascular disease (CVD) among patients with type 1 diabetes.

Methods

The EURODIAB Prospective Complications Study is a cohort including 3,250 male and female patients with type 1 diabetes (mean age 32.7 ± 10.2 years) from 16 European countries, of whom 1,880 participated in follow-up examinations. In analysis 1 (longitudinal), the association of baseline PA (based on the reported number of hours per week spent in mild, moderate and vigorous PA) with all-cause mortality and incident CVD was examined by performing survival analysis. In analysis 2 (cross-sectional), we focused on the association between PA at follow-up (data on sports, walking distance and regular bicycling) and prevalent CVD by performing logistic regression analysis. Adjustments were made for age, sex, BMI, smoking, consumption of alcohol, consumption of certain nutrients and diabetic complications.

Results

Analysis 1 (longitudinal): participation in moderate or vigorous PA once a week or more was borderline inversely associated with all-cause mortality (men and women combined) (HR 0.66, 95% CI 0.42, 1.03) and incident CVD (women only) (HR 0.66, 95% CI 0.40, 1.08). No association was found in men. Analysis 2 (cross-sectional): total PA (indexed by sports, walking, bicycling) and distance walked were inversely associated with prevalent CVD (ORtotalPA 0.66, 95% CI 0.45, 0.97; and ORwalking 0.61, 95% CI 0.42, 0.89).

Conclusions/interpretation

PA showed a borderline inverse association with both all-cause mortality (both sexes) and incident CVD (women only) in patients with type 1 diabetes. Since this is an under-researched clinical population, future longitudinal studies with objective PA measurements are needed to expand on these results.
Appendix
Available only for authorised users
Literature
1.
Chaturvedi N (2007) The burden of diabetes and its complications: trends and implications for intervention. Diabetes Res Clin Pract 76(Suppl 1):S3–S12PubMedCrossRef
2.
Morrish NJ, Wang SL, Stevens LK, Fuller JH, Keen H (2001) Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia 44(Suppl 2):S14–S21PubMedCrossRef
3.
Warburton DE, Nicol CW, Bredin SS (2006) Health benefits of physical activity: the evidence. Can Med Assoc J 174:801–809CrossRef
4.
Sigal RJ, Kenny GP, Wasserman DH, Castaneda-Sceppa C (2004) Physical activity/exercise and type 2 diabetes. Diabetes Care 27:2518–2539PubMedCrossRef
5.
Stewart KJ (2002) Exercise training and the cardiovascular consequences of type 2 diabetes and hypertension: plausible mechanisms for improving cardiovascular health. JAMA 288:1622–1631PubMedCrossRef
6.
Atkinson MA, Eisenbarth GS (2001) Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 358:221–229PubMedCrossRef
7.
8.
Moy CS, Songer TJ, LaPorte RE et al (1993) Insulin-dependent diabetes mellitus, physical activity, and death. Am J Epidemiol 137:74–81PubMed
9.
Kriska AM, LaPorte RE, Patrick SL, Kuller LH, Orchard TJ (1991) The association of physical activity and diabetic complications in individuals with insulin-dependent diabetes mellitus: the Epidemiology of Diabetes Complications Study–VII. J Clin Epidemiol 44:1207–1214PubMedCrossRef
10.
LaPorte RE, Dorman JS, Tajima N et al (1986) Pittsburgh Insulin-Dependent Diabetes Mellitus Morbidity and Mortality Study: physical activity and diabetic complications. Pediatrics 78:1027–1033PubMed
11.
Waden J, Forsblom C, Thorn LM et al (2008) Physical activity and diabetes complications in patients with type 1 diabetes: the Finnish Diabetic Nephropathy (FinnDiane) Study. Diabetes Care 31:230–232PubMedCrossRef
12.
Chimen M, Kennedy A, Nirantharakumar K, Pang TT, Andrews R, Narendran P (2012) What are the health benefits of physical activity in type 1 diabetes mellitus? A literature review. Diabetologia 55:542–551PubMedCrossRef
13.
The EURODIAB IDDM Complications Study (1994) Microvascular and acute complications in IDDM patients: the EURODIAB IDDM Complications Study. Diabetologia 37:278–285CrossRef
14.
Chaturvedi N, Sjoelie AK, Porta M et al (2001) Markers of insulin resistance are strong risk factors for retinopathy incidence in type 1 diabetes. Diabetes Care 24:284–289PubMedCrossRef
15.
Koivisto VA, Stevens LK, Mattock M et al (1996) Cardiovascular disease and its risk factors in IDDM in Europe. EURODIAB IDDM Complications Study Group. Diabetes Care 19:689–697PubMedCrossRef
16.
Demakakos P, Hamer M, Stamatakis E, Steptoe A (2010) Low-intensity physical activity is associated with reduced risk of incident type 2 diabetes in older adults: evidence from the English Longitudinal Study of Ageing. Diabetologia 53:1877–1885PubMedCrossRef
17.
Hamer M, Molloy GJ, de Oliveira C, Demakakos P (2009) Leisure time physical activity, risk of depressive symptoms, and inflammatory mediators: the English Longitudinal Study of Ageing. Psychoneuroendocrinology 34:1050–1055PubMedCrossRef
18.
Ainsworth BE, Haskell WL, Whitt MC et al (2000) Compendium of physical activities: an update of activity codes and MET intensities. Med Sci Sports Exerc 32:S498–S504PubMedCrossRef
19.
Chobanian AV, Bakris GL, Black HR et al (2003) Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42:1206–1252PubMedCrossRef
20.
Bucolo G, David H (1973) Quantitative determination of serum triglycerides by the use of enzymes. Clin Chem 19:476–482PubMed
21.
Siedel J, Hagele EO, Ziegenhorn J, Wahlefeld AW (1983) Reagent for the enzymatic determination of serum total cholesterol with improved lipolytic efficiency. Clin Chem 29:1075–1080PubMed
22.
Warnick GR, Albers JJ (1978) A comprehensive evaluation of the heparin-manganese precipitation procedure for estimating high density lipoprotein cholesterol. J Lipid Res 19:65–76PubMed
23.
Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499–502PubMed
24.
John WG, Gray MR, Bates DL, Beacham JL (1993) Enzyme immunoassay—a new technique for estimating hemoglobin A1c. Clin Chem 39:663–666PubMed
25.
Chaturvedi N, Bandinelli S, Mangili R, Penno G, Rottiers RE, Fuller JH (2001) Microalbuminuria in type 1 diabetes: rates, risk factors and glycemic threshold. Kidney Int 60:219–227PubMedCrossRef
26.
Hanas R, John G, International HBA Consensus Committee (2010) 2010 consensus statement on the worldwide standardization of the hemoglobin A1C measurement. Diabetes Care 33:1903–1904PubMedCrossRef
27.
Hoelzel W, Weykamp C, Jeppsson JO et al (2004) IFCC reference system for measurement of hemoglobin A1c in human blood and the national standardization schemes in the United States, Japan, and Sweden: a method-comparison study. Clin Chem 50:166–174PubMedCrossRef
28.
Toeller M, Klischan A, Heitkamp G et al (1996) Nutritional intake of 2868 IDDM patients from 30 centres in Europe. EURODIAB IDDM Complications Study Group. Diabetologia 39:929–939PubMedCrossRef
29.
Mann JI, de Leeuw I, Hermansen K et al (2004) Evidence-based nutritional approaches to the treatment and prevention of diabetes mellitus. Nutr Metab Cardiovasc Dis 14:373–394PubMedCrossRef
30.
Aldington SJ, Kohner EM, Meuer S, Klein R, Sjolie AK (1995) Methodology for retinal photography and assessment of diabetic retinopathy: the EURODIAB IDDM complications study. Diabetologia 38:437–444PubMedCrossRef
31.
Kearney EM, Mount JN, Watts GF, Slavin BM, Kind PR (1987) Simple immunoturbidimetric method for determining urinary albumin at low concentrations using Cobas-Bio centrifugal analyser. J Clin Pathol 40:465–468PubMedCrossRef
32.
The Consensus Committee of the American Autonomic Society and the American Academy of Neurology (1996) Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. Neurology 46:1470CrossRef
33.
Prineas RJ, Crow RS, Blackburn H (1982) The Minnesota code manual of electrocardiographic findings. John Wright-PSG, Boston
34.
Soedamah-Muthu SS, Chaturvedi N, Witte DR, Stevens LK, Porta M, Fuller JH (2008) Relationship between risk factors and mortality in type 1 diabetic patients in Europe: the EURODIAB Prospective Complications Study (PCS). Diabetes Care 31:1360–1366PubMedCrossRef
35.
Smith TC, Wingard DL, Smith B, Kritz-Silverstein D, Barrett-Connor E (2007) Walking decreased risk of cardiovascular disease mortality in older adults with diabetes. J Clin Epidemiol 60:309–317PubMedCrossRef
36.
Hamer M, Chida Y (2008) Walking and primary prevention: a meta-analysis of prospective cohort studies. Br J Sports Med 42:238–243PubMedCrossRef
37.
World Health Organization (2003) Recommendations for preventing cardiovascular diseases; In: Diet, nutrition and the prevention of chronic diseases. World Health Organization technical report series 916: i–viii, 81–94, backcover
38.
Matthews CE (2002) Use of self-report instruments to assess physical activity. In: Welk GJ (ed) Physical activity assessments for health-related research. Human Kinetics, Champaign
39.
Andersen LB, Schnohr P, Schroll M, Hein HO (2000) All-cause mortality associated with physical activity during leisure time, work, sports, and cycling to work. Arch Intern Med 160:1621–1628PubMedCrossRef
40.
Besson H, Ekelund U, Brage S et al (2008) Relationship between subdomains of total physical activity and mortality. Med Sci Sports Exerc 40:1909–1915PubMedCrossRef
41.
Stamatakis E, Hamer M, Lawlor DA (2009) Physical activity, mortality, and cardiovascular disease: is domestic physical activity beneficial? The Scottish Health Survey—1995, 1998, and 2003. Am J Epidemiol 169:1191–1200PubMedCrossRef
42.
Andersen LB (2004) Relative risk of mortality in the physically inactive is underestimated because of real changes in exposure level during follow-up. Am J Epidemiol 160:189–195PubMedCrossRef
43.
Brazeau AS, Rabasa-Lhoret R, Strychar I, Mircescu H (2008) Barriers to physical activity among patients with type 1 diabetes. Diabetes Care 31:2108–2109PubMedCrossRef
Metadata
Title
Association of physical activity with all-cause mortality and incident and prevalent cardiovascular disease among patients with type 1 diabetes: the EURODIAB Prospective Complications Study
Authors
S. M. A. J. Tielemans
S. S. Soedamah-Muthu
M. De Neve
M. Toeller
N. Chaturvedi
J. H. Fuller
E. Stamatakis
Publication date
01-01-2013
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 1/2013
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-012-2743-6

Other articles of this Issue 1/2013

Diabetologia 1/2013 Go to the issue

Research Letter

Hypoglycaemia following diabetes remission in patients with 6q24 methylation defects: expanding the clinical phenotype

Article

Effects of 12 weeks’ treatment with a proton pump inhibitor on insulin secretion, glucose metabolism and markers of cardiovascular risk in patients with type 2 diabetes: a randomised double-blind prospective placebo-controlled study

Erratum

Erratum to: A high-fat-diet-induced cognitive deficit in rats that is not prevented by improving insulin sensitivity with metformin

Article

The association of inflammatory and fibrinolytic proteins with 5 year change in insulin clearance: the Insulin Resistance Atherosclerosis Study (IRAS)

Article

Expression of the enteroviral capsid protein VP1 in the islet cells of patients with type 1 diabetes is associated with induction of protein kinase R and downregulation of Mcl-1

Letter

Endoglin (CD105) is not a specific selection marker for endothelial cells in human islets of Langerhans
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits